live_tv
Livestream Starting Soon
00
Hours
:
00
Minutes
:
00
Seconds
Up next in 10
Join this channel to get access to perks:
https://www.youtube.com/channel/UCzErXsx83tymii4SPEvndyw/join
Gilead Signs Deal to Expand HIV Drug Access in 120 Developing Countries:
Discover how Gilead's latest agreement enhances global access to HIV treatment with its groundbreaking drug, lenacapavir. This initiative aims to provide affordable, life-saving medication in over 120 developing nations, marking a significant step forward in the fight against HIV/AIDS. Learn more about the impact of this pivotal move on global healthcare access.
Gilead HIV drug access, Lenacapavir HIV treatment, Gilead HIV expansion deal, Affordable HIV medication, HIV treatment in developing countries, HIV drug access Gilead, Global HIV treatment access, Gilead lenacapavir developing countries, HIV drug lenacapavir price, Gilead signs HIV drug deal, HIV cure latest news, Gilead lenacapavir news, Expanding HIV treatment access, Gilead HIV drug licensing, Gilead healthcare deal HIV.
Show More Show Less View Video Transcript
0:00
hey everyone welcome back to the health
0:02
awareness Channel today we have some
0:04
exciting news in the global fight
0:05
against HIV pharmaceutical giant Gilead
0:08
Sciences has just announced a major deal
0:11
that could help millions of people gain
0:13
access to life-saving HIV treatment and
0:15
prevention
0:16
drugs Gilead Sciences has signed
0:19
royalty-free agreements with six generic
0:21
drug manufacturers to produce and sell
0:23
cheaper versions of its HIV prevention
0:25
drug Len capir in 120 low and middle
0:28
inome countries
0:30
this deal is a significant step toward
0:32
making affordable HIV medications
0:34
available to those who need them
0:37
most Lop ofir is a GameChanger in HIV
0:41
prevention and treatment this drug has
0:43
been shown to offer almost complete
0:45
protection from HIV infection with
0:47
trials in places like South Africa and
0:49
Uganda demonstrating its Effectiveness
0:51
especially among girls and women at high
0:54
risk of
0:54
infection the drug administered through
0:57
just two injections per year could re
0:59
solutionize HIV prevention in many
1:02
countries struggling with the
1:04
disease although Lop has not yet been
1:07
approved for HIV prevention in many
1:09
countries it is already approved as a
1:11
treatment for people with multi-drug
1:13
resistant HIV under the brand named Sun
1:15
Lanka in the US this medication has an
1:19
annual price tag of over
1:22
$42,000 however advocacy groups and
1:24
researchers say that it could be
1:25
produced for just $40 a year per patient
1:28
meaning a huge gap in affordability
1:30
especially for low income
1:32
Nations to bridge that Gap gillad has
1:35
partnered with manufacturers like Dr
1:37
re's Laboratories in India milin from
1:39
the US and other companies from Egypt
1:41
and
1:42
Pakistan these manufacturers will help
1:45
produce and distribute generic versions
1:47
of Len papaver in countries that account
1:49
for about 70% of global HIV
1:52
cases however not everyone is
1:55
celebrating while this deal covers many
1:57
countries it leaves out some with high
1:59
HIV infection rates especially in Latin
2:02
America critics argue that Gilead's
2:04
agreement focuses mainly on lower income
2:07
countries but many middle- inome
2:08
countries where new infections are
2:10
rapidly Rising are excluded this has
2:13
raised concerns that millions of people
2:14
could still be left without affordable
2:16
access to this breakthrough
2:18
drug the challenge here is ensuring that
2:21
these drugs reach all who need them
2:23
regardless of a country's income
2:25
classification Gilead's decision to not
2:27
work with the medicine patent pool which
2:29
helps make medications more widely
2:31
available is a point of contention for
2:33
many
2:34
activists despite these concerns the
2:37
move by Gilead to start filing for
2:39
Global regulatory approval for Len kavir
2:41
as an HIV prevention regimen by the end
2:44
of this year is a positive sign if
2:46
approved it could significantly reduce
2:48
the number of new infections
2:50
worldwide but many high incidence
2:53
countries including some where clinical
2:54
trials were conducted aren't included in
2:56
these agreements this leaves millions of
2:59
people without access to this
3:00
life-saving drug and that's where the
3:02
international Aid Society or is steps in
3:06
the isas is urging gilled and other
3:08
Global stakeholders to move faster and
3:10
expand access to all countries in
3:13
need I president beis grinstein has
3:16
voiced her concerns stating that while
3:18
these licensing Agreements are a step
3:20
forward large parts of the world remain
3:22
excluded some of which were involved in
3:24
the very trials that demonstrated Lena
3:26
ofir's
3:28
Effectiveness we we are hopeful that the
3:30
speed with which these agreements were
3:32
reached will be maintained and that the
3:34
rest of the world will soon benefit from
3:36
similar agreements to make Len kavir
3:38
more
3:39
affordable so why is this a big deal
3:43
well access to Affordable and effective
3:45
HIV prevention is crucial to ending the
3:47
epidemic Len kavir could be a
3:49
GameChanger for millions of people but
3:51
if it's only available in certain
3:53
countries we're not truly addressing the
3:55
global scale of the HIV
3:58
crisis right now Millions ions of people
4:00
living in high incidence areas are left
4:02
without access to not only Lenape but
4:04
also other essential HIV prevention
4:06
tools like prep while Gilead's deal will
4:10
make Len cap ofir available faster once
4:12
regulatory approval is received it's not
4:14
fast enough for those in the countries
4:16
left
4:17
out the is is calling on Gilead and
4:20
other stakeholders to prioritize people
4:22
over profits and work together to expand
4:24
access to Len cap ofir globally this
4:27
means ensuring that everyone no matter
4:29
where they live can get this life-saving
4:30
injection at an affordable
4:33
price now let's talk about what's next
4:36
Gilead has said that these agreements
4:38
were signed before Global regulatory
4:40
submissions which means that once
4:41
approval is granted the drug can hit the
4:44
market quickly in these
4:45
countries this is great news for the
4:47
regions included but what about the rest
4:49
of the
4:51
world as we've seen before it can take
4:54
years for drugs like this to reach the
4:55
most vulnerable populations especially
4:58
in countries without strong health care
5:00
infrastructures this is why advocacy
5:02
from organizations like the is is so
5:05
important they're pushing for faster and
5:07
more equitable
5:09
distribution we're also expecting more
5:12
data to be released soon at the upcoming
5:15
HIV research for prevention conference
5:17
happening October 6th to 10th 2024 new
5:20
data on Len cap ofir's efficacy and its
5:22
potential to further combat the HIV
5:24
epidemic will be
5:26
presented this will provide even more
5:28
insight into the drug role in HIV
5:32
prevention at the end of the day Len cap
5:34
ofir is just one tool in our HIV
5:37
prevention toolbox it's powerful but
5:39
it's only part of the solution to truly
5:42
end the HIV epidemic we need widespread
5:45
access to a variety of prevention and
5:46
treatment
5:48
options today there are an estimated
5:50
39.9 million people living with HIV
5:53
globally and accessible treatment is
5:55
critical to helping them live healthier
5:57
lives with the continued push for
6:00
affordable medications we hope to see a
6:02
future where HIV can be effectively
6:04
prevented and managed no matter where
6:06
you
6:07
live so what are your thoughts on this
6:10
latest development do you think Gilead's
6:12
move is a step in the right direction or
6:15
does more need to be done to ensure
6:17
access to Affordable HIV prevention and
6:19
treatment globally let us know in the
6:22
comments
6:23
below and what more can you do support
6:26
organizations like the IAS that are
6:28
advocating for Equitable access access
6:29
to HIV prevention and treatment
6:31
worldwide share this video to help raise
6:33
awareness about the importance of lenaa
6:36
and the need for Global access and of
6:39
course stay informed about the latest
6:40
developments in HIV
6:43
prevention and if you found this video
6:45
informative don't forget to hit the like
6:47
button and subscribe to the channel for
6:49
more updates on health related news and
6:51
as always stay informed and stay healthy
6:58
[Music]
#AIDS & HIV
#Public Health
#Health News